Florbenazine F18

Drug Profile

Florbenazine F18

Alternative Names: 18F-DTBZ; 18F-AV-133; 18F-FP-Dihydrotatetrabenazine; 18F-FP-DTBZ; AV-133; VMAT2 imaging - Avid Radiopharmaceuticals

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Michigan; University of Pennsylvania
  • Developer Avid Radiopharmaceuticals; Chang Gung Memorial Hospital
  • Class Contrast media; Small molecules
  • Mechanism of Action Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Parkinsonian disorders
  • Phase II/III Parkinson's disease
  • No development reported Diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Diabetes-mellitus(Diagnosis) in USA (IV, Injection)
  • 01 Mar 2016 Avid Radiopharmaceuticals completes a phase II/III trial in Parkinson's disease (Diagnosis) in Australia and USA (IV) (NCT01550484)
  • 31 Aug 2013 Phase-III clinical trials in Parkinsonian disorders in Taiwan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top